Objective: To identify the Insulin-like Growth Factor–1 (IGF-1) level of End Stage Renal Disease (ESRD) and non ESRD populations, and correlation between IGF-1level and ESRD incidences. Material & Method: This case study was carried out in Yogyakarta with 72 volunteers. The cases involved Chronic Kidney Disease (CKD) patients. The controls were non-CKD patients. CKD parameters were established with PERNEFRI diagnostic criteria. Comparison of IGF-1 levels between case and control groups was performed through ANOVA, with confidence level of 95%. Bivariate analysis to identify the correlation between IGF-1 plasma level, smoking status, illness history and body mass index (BMI) by determining odds ratio (OR) of individual risk factor of p < 0.05. Results: We enrolled 72 volunteers, 45 male and 27 female subjects. Of the 45 male patients, 15 CKD and 30 non CKD patients served as cases and controls, respectively. The difference in plasma IGF-1 level was detected in the case and control groups (42.01 ± 10.66 vs. 56.05 ± 24.91) (p < 0.05). The result of bivariate analysis showed passive smoking status, IGF-1 plasma level, DM history and hypertensive illness history had correlation with ESRD incidence with odds ratios of 7.88 (p < 0.005; CI: 1.6-37.5) for passive smokers, 4.3 (p < 0.05, CI: 1.36 to 13.33) for IGF-1 level, 21.5 (p < 0.05; CI) for DM history and 12.4 (p < 0.05; CI: 3.7 to 41) for hypertensive history. Conclusion: There was difference in IGF-1 plasma level between ESRD and non-ESRD patients. The IGF-1 plasma level, passive smoking status, diabetes history, and hypertensive history have correlation with ESRD incidence.Keywords: Insulin-like Growth Factor–1 level, End Stage Renal Disease, case control, odds ratio.
Dalrymple LS, Go AS. Epidemiology of acute infections among patients with chronic kidney disease. CJASN. 2008; 3(5): 1487-93.
Schoolwerth AC, Engelgau MM, Hostetter TH, Rufo KH, McClelan WM. Chronic kidney disease a publik health problem that needs a public health action plan. Prevention Chronic Disease. 2006; 3(2): 1-5.
Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, et al. Chronic kidney disease and mortality risk: A systematic review. J Am Soc Nephrol. 2006; 17: 2034-47.
Wakai K, Nakai S, Kikuchi K, Iseki K, Miwa N, Masakane I, et al. Trends in incidence of end-stage renal disease in japan, 1983 – 2000, age-adjusted and age-speciphic rates by gender and cause. Nephrol Dialysis Transplant. 2004; 19: 2044–52.
Hallan SI, Coresh J, Astor BC, Åsberg A, Powe NR, Romundstad S, et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol. 2006; 17: 2275-84.
Go AS, Chertow GM, Fan D, Hsu CY. Chronic kidney disease and the risk of death, cardiovascular events and hospitalization. NEJM. 2004; 351: 1296-305.
Burdick RA, Gresham JL, Woods JD, Hedderwick SA, Kurokawa K, Combe C, et al. Patterns of hepatitis B prevalence and seroconversion in hemodilysis units from three continents: The DOPPS, Kidney Int J. 2003; 63: 2222-9.
Sukhanov S, Higashi Y, Shai SY, Vaughn C, Mohler J, Li Y, et al. IGF-1 reduces inflammatory responses, suppresses oxidative stress, and decreases atherosclerosis progression in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2007; 27(12): 2684-90.
Baggio B, Budakovic A, Dalla M, Saller A, Bruseghin M, Fioretto P. Effects of cigarrete smoking on glomerular srtuctur and function in type 2 diabetic patient. J Am soc Nephrol. 2002; 43: 210-6.
Orth SR, Ogata H, Ritz E. Smoking and kidney. Nephrol Dial Transplant. 2000; 15: 1509-11.
Ejerblad E, Fored CM, Linblad P, Fryzek J, Dickman PW. Association between smoking and chronic renal failure in a nationwide population-based case control study. J Am Soc Nephrol. 2004; 15: 2178-85.
Juul A, Scheike T, Davidsen M. Low serum IGF-1 is associated with increased risk of ischemic hearth disease. Circulation. 2002; 106: 939-44.
Kawachi S, Takeda N, Sasaki A, Kakubo Y. Circulating IGF-1 and IGFBP-3 are associated with early carotid atheroschlerosis. Arterioscler Tromb Vasc Biol. 2005; 25: 617-21.
Rietveld I, Hofman A, Janssen JAM, Pols HAP. A Polymorphisme in the IGF-1 gene influences the age –related decline in circulating total IGF-1 levels. European Journal of Endocrinology. 2003; 148: 171-5.
Bakri S. Deteksi dini dan upaya-upaya pencegahan progresifitas penyaki gagal ginjal kronik. Jurnal Medika Nusantara. 2005; 26(3): 36-9.
Agarwal R, Andersens MJ. Correlates of systolic hypertension in patients with chronic kidney disease, Hypertension. J Am Soc Nephrol. 2005; 46: 514-20.
Kher V. End stage renal disease in developing countries. J. Kidney Int. 2002; 62: 350-62.
Siestma SJP, Mulder J, Janssen WMT, Hillege HL. Smoking is related to abnormal renal function in nondiabetic persons. Ann Intern Med. 2000; 133: 585-91.
Mcclellan WM, Flanders WD. Risk factor for progressive chronic kidney disease. J Ant Soc Nephrol. 2003; 14: s65-s70.
Delafontaine P, Song YH, Li Y. Expression, regulation and function of IGF-1, IGF-1R and IGFBP-1 in blood vessel. Arterioschler Thromb Vasc Biol. 2004; 24: 435-44.
Hidayati T, Purnomo H, Suhardi. Hubungan hipertensi, merokok dan minuman suplemen dengan kejadian GGKT di RSU PKU muhamadiyah Yogyakarta. Thesis. Yogyakarta: Pasca Sarjana UGM; 2007.
Adzura S, Muhaya M, Normalina M, Zaleha AM, Ezat WPS, Tajunisah I. Correlation of serum insulin like growth factor-I with retinopathy in Malaysian pregnant diabetics. Int J Ophthalmol. 2011; 4(1).
Zuppi C, Simpore J, Zappacosta B, Carrozza C, Malaguarnera M, Musumeci S. Somatomedin C (IGF-1), Dehydroepiandrosterone Sulphate (DHEA-S) and Hcy metabolism in postmenopausal African women. J Med Sci. 2006; 6(5): 734-42.